CAI
Caris Life Sciences, Inc. Common Stock
NASDAQ: CAI · HEALTHCARE · BIOTECHNOLOGY
$17.77
-3.63% today
Updated 2026-04-29
Market cap
$5.02B
P/E ratio
—
P/S ratio
6.19x
EPS (TTM)
$-3.22
Dividend yield
—
52W range
$16 – $43
Volume
2.3M
Caris Life Sciences, Inc. Common Stock (CAI) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-8.39%
Operating margin
30.20%
ROE
-45.40%
ROA
3.84%
Debt/equity
0.89x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2005 | $61.59M | $9.99M | 100.00% | 39.19% | 16.22% |
| 2006 | $18.61M | $5.23M | 93.69% | 64.73% | 28.12% |
| 2007 | $64.87M | $19.23M | 93.78% | 61.56% | 29.65% |
| 2008 | $83.14M | $-26.95M | 94.14% | 53.27% | -32.42% |
| 2009 | $65.26M | $13.56M | 86.64% | 34.99% | 20.77% |
| 2010 | $77.90M | $28.38M | 92.08% | 47.45% | 36.44% |
| 2011 | $125.71M | $50.19M | 95.61% | 51.15% | 39.93% |
| 2012 | $173.93M | $63.47M | 72.20% | 52.10% | 36.49% |
| 2013 | $212.41M | $63.93M | 68.41% | 47.74% | 30.10% |
| 2014 | $227.59M | $60.27M | 65.74% | 42.63% | 26.48% |
| 2015 | $249.67M | $26.84M | 50.43% | 27.27% | 10.75% |
| 2016 | $294.35M | $6.00M | 46.71% | 22.41% | 2.04% |
| 2017 | $348.39M | $72.06M | 48.59% | 30.33% | 20.68% |
| 2018 | $432.10M | $78.60M | 49.44% | 34.43% | 18.19% |
| 2019 | $416.54M | $31.01M | 48.14% | 31.28% | 7.44% |
| 2020 | $294.01M | $27.73M | 62.64% | 47.31% | 9.43% |
| 2022 | $258.49M | $-320.83M | 30.96% | -122.16% | -124.12% |
| 2023 | $306.13M | $-341.42M | 29.17% | -104.38% | -111.53% |
| 2024 | $412.26M | $-281.89M | 43.37% | -62.37% | -68.38% |
| 2025 | $812.03M | $-537.96M | 66.40% | 5.56% | -66.25% |